Identification of Side Effects Associated With Intolerance to BCR-ABL Inhibitors in Patients With Chronic Myeloid Leukemia
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 A change in treatment may be required for a small subset of patients who develop clinical intolerance to BCR-ABL inhibitor-associated side effects. C hronic myeloid leukemia (CML) is a hematologic disorder accounting for 15%-20% of all adult leukemias (Ault, 2007) . The disease course of CML is usually triphasic, most often initiating in a chronic phase (CP), which is asymptomatic in 40% of patients (Alvarez, Kantarjian, & Cortes, 2007) . Patients may progress to an accelerated phase (AP) and ultimately to blast phase (BP). The disease is characterized by the presence of the Philadelphia chromosome (Ph), a reciprocal translocation between chromosomes 9 and 22. The resulting fusion protein from Ph, called BCR-ABL, functions as a constitutively active tyrosine kinase and is responsible for the pathophysiology of CML (D'Antonio, 2005) . The treatments of choice for patients with CML are tyrosine kinase inhibitors that target BCR-ABL and mitigate its activity. BCR-ABL inhibitors currently approved by the U.S. Food and Drug Administration (FDA) for the treatment of CML include imatinib, dasatinib, and nilotinib. All BCR-ABL inhibitors are associated with side effects that require early recognition, vigilance, and appropriate treatment to ensure optimum outcomes. Oncology nurses play an integral role in that process; however, even with the best patient care, therapyrelated toxicity is unavoidable and may require adjustments or an alternative therapeutic strategy.
Clinical intolerance to one of the available BCR-ABL inhibitors occurs when the toxicity of the medication outweighs the clinical
